Versant Vantage II GP, L.P.
SEC CIK 1839790 · EDGAR
BoughtSold
Most active insiders at LENZ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Versant Vantage II GP-GP, LLC | 10% | — | $10.35M |
| 2 | Olsson Shawn | Chief Commercial Off | — | $261.0K |
| 3 | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | $251.4K | — |
| 4 | MCCOLLUM JAMES W | Dir | $239.3K | — |
| 5 | Chevallard Daniel R. | CFO | $114.3K | — |
| 6 | George Jeffrey P. | Dir | $49.9K | — |
Versant Vantage II GP, L.P. made no open-market trades at LENZ in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-03-25 | 2024-03-21 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP, L.P. | 10% | J - Other | — | +598.2K | 842.2K | +245% | — |
| 2022-08-11 | 2022-08-09 | IPSC | Century Therapeutics, Inc. | Versant Vantage II GP, L.P. | 10% | J - Other | $0.00 | -364.8K | 11.45M | -3% | $0 | |
| 2022-08-11 | 2022-08-09 | IPSC | Century Therapeutics, Inc. | Versant Vantage II GP, L.P. | 10% | S - Sale | $13.03 | -550.0K | 11.82M | -4% | -$7.17M |
Purchase Sale Sale after option exercise All abbreviations